Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.

[1]  H. Levin,et al.  Intermediate‐Term Outcome with Radical Prostatectomy for Localized Prostate Cancer: The Cleveland Clinic Experience , 2001 .

[2]  P. Troncoso,et al.  Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Catalona,et al.  Contemporary results of anatomic radical prostatectomy , 1999, CA: a cancer journal for clinicians.

[4]  W. Catalona,et al.  Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. , 1998, The Journal of urology.

[5]  H. Levin,et al.  Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. , 1998, Urology.

[6]  R. Millikan,et al.  Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[8]  A. Partin,et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.

[9]  H. Levin,et al.  External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. , 1997, The cancer journal from Scientific American.

[10]  H. Levin,et al.  Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. , 1996, Urology.

[11]  S. Mani,et al.  Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? , 1996, Hematology/oncology clinics of North America.

[12]  D. Wood,et al.  Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .

[13]  L. Baert,et al.  Morphologic and lmmunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies , 1994, Cancer.

[14]  B. Redman,et al.  Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Logothetis,et al.  Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Tew,et al.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Klein,et al.  Acute complications after radical retropubic prostatectomy , 2000 .